List of PDP proposals submitted in the 2017 s round

Transcrição

1 List of PDP proposals submitted in the 2017 s round # PRODUCT PUBLIC INSTITUTION PRIVATE ENTITY PROTOCOL # 1 adalimumab Butantan Libbs 2 adalimumab 3 adalimumab TECPAR 4 betagalsidase TECPAR 5 capecitabine IVB 6 capecitabine FUNED 7 capecitabine LAFEPE Bionovis S/A Merck S/A Ares Trading Orygen Biotecnologia S/A Pfizer Incorporated Genzyme Corporation (Holder- EUA) Genzyme Ireland LTD (Holder) Genzyme Brasil Ltda (Affiliate) capecitabine LAQFA 9 certolizumab 10 coagulation factor concentrate (factors i,ix, vii recombinant, viii associated with willebrand factor, viii plasma, xiii) TECPAR 11 daclatasvir LFM 12 daclatasvir 13 daclatasvir LAQFA 14 daclatasvir FURP 15 darunavir LAFEPE 16 darunavir LAQFA 17 darunavir FURP 18 darunavir + ritonavir IVB * Globe Química S.A Octapharma AG Janssen-Cilag Farmaceutica Ltda Aurobindo Pharma Indústria Rio de Janeiro Sao Paulo Tokyo lickslegal.com 1/5

2 19 dasatinib IVB 20 dasatinib FUNED 21 dasatinib LAQFA 22 dasatinib FURP 23 dolutegravir LAFEPE 24 dolutegravir LAQFA 25 dolutegravir FURP 26 dolutegravir + lamivudine IVB 27 entricitabine + tenofovir 28 entricitabine + tenofovir IVB 29 entricitabine + tenofovir NUPLAM 30 entricitabine + tenofovir 31 erlotinib IVB 32 erlotinib FUNED 33 erlotinib LAFEPE 34 erlotinib LAQFA 35 erlotinib TECPAR 36 everolimus 37 everolimus NUPLAM 38 everolimus 39 everolimus FURP farmacêutica S/A Aurobindo Pharma Indústria Blanver farmoquímica e Gilead Sciences Farmacêutica do Brasil Ltda Nortec S/A ITF Chemical Ltda Cipla Limited Libbs Farmacêutica LTDA Rio de Janeiro Sao Paulo Tokyo lickslegal.com 2/5

3 40 everolimus TECPAR 41 fingolimod LIFESA 42 fingolimod LAFEPE 43 fingolimod NUPLAM 44 fingolimod FURP 45 golimumab 46 hydroxyurea IVB 47 hydroxyurea 48 imiglucerase TECPAR insulin aspart (ultra-fast rapid-acting insulin) Butantan FUNED 53 lenalidomide FUNED 54 lenalidomide TECPAR 55 mycophenolate sodium LQFEX 56 mycophenolate sodium IVB 57 mycophenolate sodium 58 mycophenolate sodium FURP 59 nilotinib IVB 60 nilotinib LAQFA 61 nivolumab 62 oseltamivir LAFEPE Novartis Biociências S/A Novartis Biociência S/A Janssen Genzyme Corporation - (Holder EUA) Genzyme Ireland LTD (Holder) Genzyme do Brasil Ltda (Affiliate) INDAR, PrJSC Sanofi-Aventis Deutschland GmbH Biomm S.A Gan & Lee Pharmaceuticals INDAR, PrJSC a Natcofarma do Brasil a Natcofarma do Brasil Novartis Pharma AG Rio de Janeiro Sao Paulo Tokyo lickslegal.com 3/5

4 63 oseltamivir LAQFA 64 oseltamivir FURP 65 palivizumab Butantan Libbs 66 pembrolizumab 67 pramipexole NUPLAM 68 simeprevir LFM 69 simeprevir 70 simeprevir LAQFA 71 simeprevir FURP 72 sofosbuvir LFM 73 sofosbuvir 74 sofosbuvir LAFEPE 75 sofosbuvir LAQFA 76 sofosbuvir FURP 77 supplement of vitamins and minerals in powder (micronutrients) LFM 78 teriflunomide LFM 79 teriflunomide NUPLAM UFCG.. Gilead Sciences Farmacêutica do Brasil Ltda Nortec S/A DSM Produtos Nutricionais BRASIL S/A LAQFA* Natco Pharma Limited Innovita Biological Technology Co., Ltd. Genbody Inc Rio de Janeiro Sao Paulo Tokyo lickslegal.com 4/5

5 82 83 tocilizumab FURP Innovita Biological Technology Co., Ltd. Ares Trading (Merck S/A, Merck Serono) * This seems to be a clerical mistake since /LAQFA is a public institution, not a Private Entity. Rio de Janeiro Sao Paulo Tokyo lickslegal.com 5/5